Esketamine for treatment resistant depression

References

• Patten SB, Williams JVA, Lavorato DH, et al. Descriptive epidemiology of major depressive disorder in Canada in 2012. Can J Psychiatry. 2015;60:23–30.
   PubMed Web of Science ®Google Scholar
• Ustün TB, Ayuso-Mateos JL, Chatterji S, et al. Global burden of depressive disorders in the year 2000. Br J Psychiatry. 2004;184:386–392.
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905–1917.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Filteau M-J, Martin L, et al. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord. 2014;156:1–7.
   PubMed Web of Science ®Google Scholar
• Cleare A, Pariante CM, Young AH, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol (Oxford). 2015;29:459–525.
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Lam RW, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. pharmacological treatments. Can J Psychiatry. 2016;61:540–560.
   PubMed Web of Science ®Google Scholar
• Folkerts HW, Michael N, Tölle R, et al. Electroconvulsive therapy vs. paroxetine in treatment-resistant depression — a randomized study. Acta Psychiatrica Scand. 1997;96:334–342.
   PubMed Web of Science ®Google Scholar
• UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet. 2003;361:799–808.
   PubMed Web of Science ®Google Scholar
• Berlim MT, McGirr A, Van den Eynde F, et al. Effectiveness and acceptability of deep brain stimulation (DBS) of the subgenual cingulate cortex for treatment-resistant depression: a systematic review and exploratory meta-analysis. J Affect Disord. 2014;159:31–38.
   PubMed Web of Science ®Google Scholar
• Martin JLR, Martín-Sánchez E. Systematic review and meta-analysis of vagus nerve stimulation in the treatment of depression: variable results based on study designs. Eur Psychiatry. 2012;27:147–155.
   PubMed Web of Science ®Google Scholar
• Schlaepfer TE, Frick C, Zobel A, et al. Vagus nerve stimulation for depression: efficacy and safety in a European study. Psychol Med. 2008;38:651–661.
   PubMed Web of Science ®Google Scholar
• Berlim MT, Van Den Eynde F, Jeff Daskalakis Z. Clinically meaningful efficacy and acceptability of low-frequency repetitive transcranial magnetic stimulation (rTMS) for treating primary major depression: a meta-analysis of randomized, double-blind and sham-controlled trials. Neuropsychopharmacology. 2013;38:543–551.
   PubMed Web of Science ®Google Scholar
• Berlim MT, van Den Eynde F, Tovar-Perdomo S, et al. Response, remission and drop-out rates following high-frequency repetitive transcranial magnetic stimulation (rTMS) for treating major depression: a systematic review and meta-analysis of randomized, double-blind and sham-controlled trials. Psychol Med. 2014;44:225–239.
   PubMed Web of Science ®Google Scholar
• Cao X, Deng C, Su X, et al. Response and remission rates following high-frequency vs. low-frequency repetitive transcranial magnetic stimulation (rTMS) over right DLPFC for treating major depressive disorder (MDD): a meta-analysis of randomized, double-blind trials. Front Psychiatry. 2018;9:413.
   PubMed Web of Science ®Google Scholar
• Senova S, Cotovio G, Pascual-Leone A, et al. Durability of antidepressant response to repetitive transcranial magnetic stimulation: systematic review and meta-analysis. Brain Stimul. 2019;12:119–128.
   PubMed Web of Science ®Google Scholar
• Anis NA, Berry SC, Burton NR, et al. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol. 1983;79:565–575.
   PubMed Web of Science ®Google Scholar
• Lodge D, Anis NA, Burton NR. Effects of optical isomers of ketamine on excitation of cat and rat spinal neurones by amino acids and acetylcholine. Neurosci Lett. 1982;29:281–286.
   PubMed Web of Science ®Google Scholar
• Miller OH, Moran JT, Hall BJ. Two cellular hypotheses explaining the initiation of ketamine’s antidepressant actions: direct inhibition and disinhibition. Neuropharmacology. 2016;100:17–26.
   PubMed Web of Science ®Google Scholar
• Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351–354.
   PubMed Web of Science ®Google Scholar
• Murrough JW, Perez AM, Pillemer S, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013;74:250–256.
   PubMed Web of Science ®Google Scholar
• Coyle CM, Laws KR. The use of ketamine as an antidepressant: a systematic review and meta-analysis. Hum Psychopharmacol. 2015;30:152–163.
   PubMed Web of Science ®Google Scholar
• Thomas RK, Baker G, Lind J, et al. Rapid effectiveness of intravenous ketamine for ultraresistant depression in a clinical setting and evidence for baseline anhedonia and bipolarity as clinical predictors of effectiveness. J Psychopharmacol (Oxford). 2018;32:1110–1117.
   PubMed Web of Science ®Google Scholar
• Archer S, Chrenek C, Swainson J. Maintenance ketamine therapy for treatment-resistant depression. J Clin Psychopharmacol. 2018;38:380–384.
   PubMed Web of Science ®Google Scholar
• Lapidus KAB, Levitch CF, Perez AM, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry. 2014;76:970–976.
   PubMed Web of Science ®Google Scholar
• Gálvez V, Li A, Huggins C, et al. Repeated intranasal ketamine for treatment-resistant depression - the way to go? Results from a pilot randomised controlled trial. J Psychopharmacol (Oxford). 2018;32:397–407.
   PubMed Web of Science ®Google Scholar
• Lee V, Archer S, Chrenek C, et al. A response to: repeated intranasal ketamine for treatment resistant depression: the way to go? Results from a pilot randomised controlled trial. J Psychopharmacol (Oxford). 2019;33:258–259.
   PubMed Web of Science ®Google Scholar
• Abdallah CG, Adams TG, Kelmendi B, et al. Ketamine’s mechanism of action: a path to rapid-acting antidepressants. Depress Anxiety. 2016;33:689–697.
   PubMed Web of Science ®Google Scholar
• Baker GB, Prior TI. Stereochemistry and drug efficacy and development: relevance of chirality to antidepressant and antipsychotic drugs. Ann Med. 2002;34:537–543.
   PubMed Web of Science ®Google Scholar
• Andrade C. Ketamine for depression, 3: does chirality matter? J Clin Psychiatry. 2017;78:e674–e677.
   PubMed Web of Science ®Google Scholar
• Muller J, Pentyala S, Dilger J, et al. Ketamine enantiomers in the rapid and sustained antidepressant effects. Ther Adv Psychopharmacol. 2016;6:185–192.
   PubMed Web of Science ®Google Scholar
• Peltoniemi MA, Hagelberg NM, Olkkola KT, et al. Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. Clin Pharmacokinet. 2016;55:1059–1077.
   PubMed Web of Science ®Google Scholar
• Pfenninger EG, Durieux ME, Himmelseher S. Cognitive impairment after small-dose ketamine isomers in comparison to equianalgesic racemic ketamine in human volunteers. Anesthesiology. 2002;96:357–366.
   PubMed Web of Science ®Google Scholar
• Singh JB. Antidepressant efficacy and dosing comparisons of ketamine enantiomers: response to Hashimoto. Am J Psychiatry. 2016;173:1045–1046.
   PubMed Web of Science ®Google Scholar
• White PF, Schüttler J, Shafer A, et al. Comparative pharmacology of the ketamine isomers. Studies in volunteers. Br J Anaesth. 1985;57:197–203.
   Google Scholar
• Fukumoto K, Toki H, Iijima M, et al. Antidepressant potential of (R)-ketamine in rodent models: comparison with (S)-ketamine. J Pharmacol Exp Ther. 2017;361:9–16.
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Kakiuchi T, Ohba H, et al. Reduction of dopamine D2/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys. Eur Arch Psychiatry Clin Neurosci. 2017;267:173–176.
   PubMed Web of Science ®Google Scholar
• Yang C, Shirayama Y, Zhang J-C, et al. R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry. 2015;5:e632.
   PubMed Web of Science ®Google Scholar
• Yang C, Han M, Zhang J-C, et al. Loss of parvalbumin-immunoreactivity in mouse brain regions after repeated intermittent administration of esketamine, but not R-ketamine. Psychiatry Res. 2016;239:281–283.
   PubMed Web of Science ®Google Scholar
• Zhang J-C, Li S-X, Hashimoto K. R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacol Biochem Behav. 2014;116:137–141.
   PubMed Web of Science ®Google Scholar
• Zanos P, Moaddel R, Morris PJ, et al. Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol Rev. 2018;70:621–660.
   PubMed Web of Science ®Google Scholar
• Tian Z, Dong C, Fujita A, et al. Expression of heat shock protein HSP-70 in the retrosplenial cortex of rat brain after administration of (R,S)-ketamine and (S)-ketamine, but not (R)-ketamine. Pharmacol Biochem Behav. 2018;172:17–21.
   PubMed Web of Science ®Google Scholar
• Zhang K, Hashimoto K. An update on ketamine and its two enantiomers as rapid-acting antidepressants. Expert Rev Neurother. 2019;19:83–92.
   PubMed Web of Science ®Google Scholar
• Chang L, Zhang K, Pu Y, et al. Comparison of anatidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine and (S)-ketamine. Pharmacol Biochem Behav. 2019;181:53–59.
   PubMed Web of Science ®Google Scholar
• Mathisen LC, Skjelbred P, Skoglund LA, et al. Effect of ketamine, an NMDA receptor inhibitor, in acute and chronic orofacial pain. Pain. 1995;61:215–220.
   PubMed Web of Science ®Google Scholar
• Hashimoto K. Ketamine’s antidepressant action: beyond NMDA receptor inhibition. Expert Opin Ther Targets. 2016;20:1389–1392.
   PubMed Web of Science ®Google Scholar
• Moghaddam B, Adams B, Verma A, et al. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci. 1997;17:2921–2927.
   PubMed Web of Science ®Google Scholar
• Autry AE, Adachi M, Nosyreva E, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 2011;475:91–95.
   PubMed Web of Science ®Google Scholar
• Li N, Lee B, Liu R-J, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329:959–964.
   PubMed Web of Science ®Google Scholar
• Abdallah CG, Averill LA, Gueorguieva R, et al. Rapamycin, an immunosuppressant and mTORC1 inhibitor, triples the antidepressant response rate of ketamine at 2 weeks following treatment. A double-blind, placebo-controlled, cross-over, randomized clinical trial. bioRxiv preprint first posted online. 2018 Dec 19. DOI:10.1101/500959.
   Google Scholar
• Zanos P, Moaddel R, Morris PJ, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016;533:481–486.
   PubMed Web of Science ®Google Scholar
• Chaki S. Is metabolism of (R)-ketamine essential for the antidepressant effects? Int J Neuropsychopharmacol. 2018;21:154–156.
   PubMed Web of Science ®Google Scholar
• Li L, Vlisides PE. Ketamine: 50 years of modulating the mind. Front Hum Neurosci. 2016;10:612.
   PubMed Web of Science ®Google Scholar
• Mion G, Villevieille T. Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci Ther. 2013;19:370–380.
   PubMed Web of Science ®Google Scholar
• Williams NR, Heifets BD, Blasey C, et al. Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry. 2018;175:1205–1215.
   PubMed Web of Science ®Google Scholar
• Zhang K, Hashimoto K. Lack of opioid system in the antidepressant actions of ketamine. Biol Psychiatry. 2019;85:e25–e27.
   PubMed Web of Science ®Google Scholar
• Yang Y, Cui Y, Sang K, et al. Ketamine blocks bursting in the lateral habenula to rapidly relieve depression. Nature. 2018;554:317–322.
   PubMed Web of Science ®Google Scholar
• Yanagihara Y, Ohtani M, Kariya S, et al. Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Biopharm Drug Dispos. 2003;24:37–43.
   PubMed Web of Science ®Google Scholar
• Chong C, Schug SA, Page-Sharp M, et al. Development of a sublingual/oral formulation of ketamine for use in neuropathic pain: preliminary findings from a three-way randomized, crossover study. Clin Drug Investig. 2009;29:317–324.
   PubMed Web of Science ®Google Scholar
• Fanta S, Kinnunen M, Backman JT, et al. Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing. Eur J Clin Pharmacol. 2015;71:441–447.
   PubMed Web of Science ®Google Scholar
• Brunton L, Hilal-Dandan R, Knollman B Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 13e. Minion Pro by Cenveo® Publisher Services; 2018.
   Google Scholar
• Portmann S, Kwan HY, Theurillat R, et al. Enantioselective capillary electrophoresis for identification and characterization of human cytochrome P450 enzymes which metabolize ketamine and norketamine in vitro. J Chromatogr A. 2010;1217:7942–7948.
   PubMed Web of Science ®Google Scholar
• Ihmsen H, Geisslinger G, Schüttler J. Stereoselective pharmacokinetics of ketamine: R(-)-ketamine inhibits the elimination of S(+)-ketamine. Clin Pharmacol Ther. 2001;70:431–438.
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceuticals inc. SpravatoTM (esketamine hydrochloride) [Package insert]. Copyright Janssen Pharmaceuticals; Titusville, NJ; 2019. Available from: http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/SPRAVATO-pi.pdf
   Google Scholar
• Daly EJ, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: A randomized clinical trial. JAMA Psychiatry. 2018;75:139–148.
   PubMed Web of Science ®Google Scholar
• Canuso CM, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 2018;175:620–630.
   PubMed Web of Science ®Google Scholar
• Fedgchin M, Trivedi M, Daly EJ, et al. Randomized, double-blind study of fixed-dosed intranasal esketamine plus oral antidepressant vs. active control in treatment-resistant depression. Presented at the 9th Biennial Conference of the International Society for Affective Disorders (ISAD) and the Houston Mood Disorders Conference. Houston, TX, USA, 2018 September 21.
   Google Scholar
• Lam RW, Michalak E, Swinson R. Assessment scales in depression, mania and anxiety. London: Taylor and Francis; 2005.
   Google Scholar
• Zimmerman M, Posternak MA, Chelminski I. Derivation of a definition of remission on the Montgomery-Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression. J Psychiatr Res. 2004;38:577–582.
   PubMed Web of Science ®Google Scholar
• Popova V, Daly EJ, Trivedi M, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry. 2019;176:428–438.
   PubMed Web of Science ®Google Scholar
• Ochs-Ross R, Daly EJ, Zhang Y, et al. Efficacy and safety of intranasal esketamine plus an oral antidepressant in elderly patients with treatment-resistant depression. Biol Psychiatry. 2018;83:S391.
   Web of Science ®Google Scholar
• Joyce PR, Mulder RT, Luty SE, et al. Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline. Aust N Z J Psychiatry. 2002;36:384–391.
   PubMed Web of Science ®Google Scholar
• Mynors-Wallis L, Gath D. Predictors of treatment outcome for major depression in primary care. Psychol Med. 1997;27:731–736.
   PubMed Web of Science ®Google Scholar
• Daly E, Trivedi M, Janik A, et al. A randomized withdrawal, double-blind, multicenter study of esketamine nasal spray plus an oral antidepressant for relapse prevention in treatment-resistant depression. Poster/abstract presented at Annual Meeting of the American Society of Clinical Psychopharmacology, Hollywood, Florida; May 30, 2018. Poster W68.
   Google Scholar
• Wajs E, Aluisio L, Morrison R, et al. Long-term safety of esketamine nasal spray plus an oral antidepressant in patients with treatment-resistant depression: phase 3, open label safety and efficacy study (SUSTAIN-2). Poster presented at: The American Society of Clinical Psychopharmacology Meeting; May 2018; Miami, Florida. 2018.
   Google Scholar
• Correia-Melo FS, Leal GC, Carvalho MS, et al. Comparative study of esketamine and racemic ketamine in treatment-resistant depression: protocol for a non-inferiority clinical trial. Medicine (Baltimore). 2018;97:e12414.
   PubMed Web of Science ®Google Scholar
• Short B, Fong J, Galvez V, et al. Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry. 2018;5:65–78.
   PubMed Web of Science ®Google Scholar
• Schatzberg AF. A word to the wise about intranasal esketamine. Am J Psychiatry. 2019;176:422–424.
   PubMed Web of Science ®Google Scholar
• Wan L-B, Levitch CF, Perez AM, et al. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry. 2015;76:247–252.
   PubMed Web of Science ®Google Scholar
• FDA report on esketamine for treatment resistant depression. 2019; Accessed April 9, 2019. Available from: https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM630970.pdf.
   Google Scholar
• van de Loo AJAE, Bervoets AC, Mooren L, et al. The effects of intranasal esketamine (84 mg) and oral mirtazapine (30 mg) on on-road driving performance: a double-blind, placebo-controlled study. Psychopharmacology (Berl.). 2017;234:3175–3183.
   Google Scholar
• Chu PS-K, Ma W-K, Wong SC-W, et al. The destruction of the lower urinary tract by ketamine abuse: a new syndrome?. BJU Int. 2008(102):1616-1622.
   Google Scholar
• Shahani R, Streutker C, Dickson B, et al. Ketamine-associated ulcerative cystitis: A new clinical entity. Urology. 2007;69:810–812.
   PubMed Web of Science ®Google Scholar
• Tam Y-H, Ng C-F, Pang KK-Y, et al. One-stop clinic for ketamine-associated uropathy: report on service delivery model, patients’ characteristics and non-invasive investigations at baseline by a cross-sectional study in a prospective cohort of 318 teenagers and young adults. BJU Int. 2014;114:754–760.
   PubMed Web of Science ®Google Scholar
• Tsai J-H, Tsai K-B, Jang M-Y. Ulcerative cystitis associated with ketamine. Am J Addictions. 2008;17:453.
   PubMed Web of Science ®Google Scholar
• Morrison RL, Fedgchin M, Singh J, et al. Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study. Psychopharmacology (Berl). 2018;235:1107–1119.
   PubMed Web of Science ®Google Scholar
• Morgan CJA, Riccelli M, Maitland CH, et al. Long-term effects of ketamine: evidence for a persisting impairment of source memory in recreational users. Drug Alcohol Depend. 2004;75:301–308.
   PubMed Web of Science ®Google Scholar
• Shiroma PR, Albott CS, Johns B, et al. Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression. Int J Neuropsychopharmacoly. 2014;17:1805–1813.
   PubMed Web of Science ®Google Scholar
• Unpublished data: clinical registry number 108104: a single-center, single-dose, double blind, double dummy, placeo controlled, randomized crossover study to evaluate the abuse potential of intranasal esketamine compared to racemic intravenous ketamine in nondependentm, recreational users of perception-altering drugs.
   Google Scholar
• Kolar D. Addictive potential of novel treatments for refractory depression and anxiety. Neuropsychiatr Dis Treat. 2018;14:1513–1519.
   PubMed Web of Science ®Google Scholar
• Nutt D, King LA, Saulsbury W, et al. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet. 2007;369:1047–1053.
   PubMed Web of Science ®Google Scholar
• Royal College of Psychiatrists. Statement on ketamine to treat depression. Position statement cert02/17. Approved by the Royal College of Psychiatrists, Committee on ECT and related treatments: 2017.
   Google Scholar
• Sanacora G, Frye MA, McDonald W, et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry. 2017;74:399–405.
   PubMed Web of Science ®Google Scholar
• Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97–170.
   PubMed Web of Science ®Google Scholar